3 results match your criteria: "Paris Lodron University Salzburg (PLUS)[Affiliation]"
Testing the validity of the broaden-and build theory of positive emotions: a network analytic approach.
Front Psychol
September 2024
Department of Psychology, Paris Lodron University Salzburg (PLUS), Salzburg, Austria.
Article Synopsis
- The Broaden-and-Build Theory of positive emotions suggests that positive emotions enhance cognitive flexibility and improve life outcomes, serving as a counterpoint to negative cycles in psychology.
- Two studies were conducted using network modeling with participants (312 and 302) to investigate the relationships among positive emotions, resources, and life outcomes.
- Results showed a strong connection between positive emotions and beneficial life outcomes, but questioned the intermediary role of "broadening," suggesting that the theory's current form may need revision.
Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa.
Int J Mol Sci
January 2024
EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
Antisense oligonucleotides (ASOs) represent an emerging therapeutic platform for targeting genetic diseases by influencing various aspects of (pre-)mRNA biology, such as splicing, stability, and translation. In this study, we investigated the potential of modulating the splicing pattern in recessive dystrophic epidermolysis bullosa (RDEB) patient cells carrying a frequent genomic variant (c.425A > G) that disrupts splicing in the gene by using short 2'-O-(2-Methoxyethyl) oligoribo-nucleotides (2'-MOE ASOs).
View Article and Find Full Text PDFComparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Cancer Med
August 2023
Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Background: Pancreatic cancer is mostly diagnosed in an advanced stage and treated with systemic therapy with palliative intent. Nowadays, the doublet chemotherapy of Gemcitabine and nab-paclitaxel (Gem-Nab) is one of the most frequently used regimens worldwide, but is not ubiquitarily available or reimbursed. Therefore, we compared the clinical efficacy of Gem-Nab to a historical control of patients treated with gemcitabine and oxaliplatin (Gem-Ox) at our tertiary cancer center, which was the standard treatment prior to the introduction of FOLFIRINOX.
View Article and Find Full Text PDF